

News Releases

All Years

Search

Go

[Advanced Search](#)

MAR 12, 2021

Inhibrx Reports Fourth Quarter and Fiscal Year 2020 Financial Results and Announces Phase 1 Single Agent Dose Escalation Results for INBRX-105, a Novel Targeted 4-1BB Agonist

FEB 1, 2021

Inhibrx Announces Participation in Upcoming Investor Conference

JAN 13, 2021

Inhibrx Granted Fast Track Designation for INBRX-109 for the Treatment of Unresectable or Metastatic Conventional Chondrosarcoma Patients

JAN 5, 2021

Inhibrx Announces Phase 1 Dose Escalation Results of INBRX-106, a Novel Hexavalent OX40 Agonist

NOV 13, 2020

Inhibrx Reports Financial Results for the Third Quarter 2020 and Announces Amended Loan Agreement with Oxford

Show per
page

[«](#) [1](#) [...](#) [8](#) [9](#) [10](#) [11](#) [12](#) **13** [14](#) [15](#) [16](#) [»](#)



<https://inhibrxbiosciences.investorroom.com/news-releases?l=5&o=60>